Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort
Recruiting now
Conditions studied: Obesity, Aging, Aging Problems, Metabolic Syndrome
In brief
The goal of this prospective observational study is to identify and validate blood based aging biomarkers in relation to cardiometabolic phenotypes of young and old, female and male subjects with or without obesity. The main question is to gain insights into the interaction of obesity related metabolic alteration and aging, and the relevance of loss of metabolic control in the development of age-related diseases in order to build a foundation for targeted drug- and lifestyle interventions in future studies.
Key facts
- Study ID
- NCT06511297
- Run by
- Thomas Scherer
- People needed
- 650
- Starts
- 2025-05-05
- Expected to finish
- 2036-01-01
- Last updated by the study team
- 2026-02-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Group 1 - Lean, young adults (n = 150)
- Age 18 - 35 years
- Body mass index (BMI) ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 12 months)
- Group 2 - Overweight, young adults (n = 150)
- Age 18 - 35 years
- BMI ≥ 28kg/m2 (≥ 12 months)
- Group 3 - Lean, older adults (n = 150)
- Age ≥ 60 years
- BMI ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 3 years)
- Group 4 - Overweight, older adults (n = 150)
- Age ≥ 60 years
- BMI ≥ 28 kg/m2 (≥ 3 years)
- Subgroup A (n=75): with pre-existent cardiovascular disease defined as: history of myocardial infarction or evidence of coronary artery disease irrespective of revascularization status or history of ischemic or hemorrhagic stroke or presence of peripheral artery disease or heart failure with preserved ejection fraction (NYHA Class I-II).
- Subgroup B (n=75): without pre-existent cardiovascular disease
- Group 5 - Nonagenerians Age ≥ 90 (n = 50)
- Age ≥ 90 years
- BMI ≥ 18.5 kg/m2 (≥ 3 years)
You may not qualify if…
- Group 1 - Lean, young adults (n = 150)
- Highly physical active (i.e. > 5 times sporting activity / week with moderate to high intensity [heart rate 140 - 200bpm])
- Special diets (i.e. ketogenic diet and time-restricted eating)
- Clinically significant metabolic or endocrine disorders
- Claustrophobia
- drug abuse, alcohol > 15 drinks/week
- Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions
- Metal implants that prohibit 3T MRI
- Pregnancy or breastfeeding
- Group 2 - Overweight, young adults (n = 150)
- Highly physical active (i.e. > 5 times sporting activity / week with moderate to high intensity [heart rate 140 - 200bpm])
- Special diets (i.e. ketogenic diet and time-restricted eating)
- Active anti-obesity treatment (e.g. glucagon-like peptide 1 (GLP-1) analogues, polyagonists, naltrexone and bupropion)
- Clinically significant metabolic or endocrine disorders
- Claustrophobia
- drug abuse, alcohol > 15 drinks/week
- Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions
- Metal implants that prohibit 3T MRI
- Pregnancy or breastfeeding
- Group 3 - Lean, older adults (n = 150)
- Highly physical active (i.e. > 5 times sporting activity / week with moderate to high intensity [heart rate 140 - 200bpm])
- Special diets (i.e. ketogenic diet and time-restricted eating)
- Diabetes, overt hypo/hyperthyroidism
- Claustrophobia
- drug abuse, alcohol > 15 drinks/week
Where it is running
- Medical University of Vienna — Vienna, State of Vienna, Austria (enrolling)
- Medical University of Graz — Graz, Styria, Austria (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.